

Thimerosal Content in Some US Licensed Vaccines

updated March 3, 2006

Vaccine	Brand Name	Manufacturer	Thimerosal Concentration (1)	Mercury mcg/0.5 ml	
Anthrax	Biothrax	BioPort Corp	0	0	
DTaP	Tripedia	sanofi pasteur	*	*	
	Infanrix	GlaxoSmithKline	0	0	
	Daptacel	sanofi pasteur	0	0	
DTaP-HepB-IPV	Pediarix	GlaxoSmithKline	*	*	
DTaP-Hib	TriHIBit	sanofi pasteur	*	*	
DTwP	All Products		.01%	25	
DT	Diphtheria & Tetanus Toxoids Adsorbed USP	multi-dose	.01%	25	
		single dose	*	*	
Td	DECAVAC	sanofi pasteur	*	*	
	Tetanus and Diphtheria Toxoids Adsorbed	sanofi pasteur	*	*	
Tdap	ADACEL	sanofi Pasteur	0	0	
	Boostrix	GlaxoSmithKline	0	0	
Tetanus Toxoid	Tetanus Toxoid Adsorbed USP		.01%	25	
	Tetanus Toxoid Adsorbed Adult Use	sanofi pasteur	.01%	25	
	Booster		.01%	25	
Hib	ActHIB /OmniHib	sanofi pasteur	0	0	
	HibTITER	Wyeth-Ayerst	0	0	
	PedvaxHIB liquid (2)	Merck	0	0	
Hib-HepB	Comvax (3)	Merck	0	0	
Hepatitis A	Havrix	GlaxoSmithKline	0	0	
	Vaqta adult/pediatric	Merck	0	0	
Hepatitis B	Engerix-B preservative free	GlaxoSmithKline	*	*	
	Recombivax HB preservative free	Merck	0	0	
Hep A-B	Twinrix	GlaxoSmithKline	*	*	
Influenza 2004 /5 Formula	Fluzone	prefilled syringe (0.25 mL)	*	*	
		prefilled syringe (0.5mL)	sanofi pasteur	.01%	25
		multi-dose (5 mL)		.01%	25
	Fluvirin preservative free	Evans	*	*	
	Fluvirin		.01%	25	
	FluMist	MedImmune	0	0	
2005-6 Formula	Fluarix	GlaxoSmithKline	*	*	
IPV	IPOL	sanofi pasteur	0	0	
Meningococcal	Menactra	sanofi Pasteur	0	0	
	MENOMUNE-A/C/Y/W-135	multi-dose	.01%	25	
		single dose	*	*	
MMR	M-M-R II	Merck	0	0	
MMR-Varicella	ProQuad	Merck	0	0	
Pneumococcal	Prenar	Wyeth-Ayerst	0	0	
	Pneumovax 23	Merck	0	0	
Rabies	RabAvert	Chiron	0	0	
	IMOVAX	sanofi pasteur	0	0	
Rotavirus	RotaTaq	Merck	0	0	
Typhoid Fever	Typhim Vi	sanofi pasteur	0	0	
	Vivotif	Berna Biotch	0	0	
Varicella	Varivax	Merck	0	0	
Yellow Fever	YF-VAX	sanofi pasteur	0	0	

1. A concentration of 1:10,000 is equivalent to a 0.01% concentration. Thimerosal is approximately 50% Hg by weight. A 1:10,000 concentration contains 25 micrograms of Hg per 0.5 mL.

2. A previously marketed lyophilized preparation contained 0.005% thimerosal.

3. COMVAX is not approved for use under 6 weeks of age because of decreased response to the Hib component.

* This product should be considered equivalent to thimerosal-free products. The trace amounts (<0.3 mcg) of mercury left after post-production thimerosal removal have no biological effect. JAMA 1999;282(18) and JAMA 2000;283(16).

Institute for Vaccine Safety



Johns Hopkins University
www.vaccinesafetv.edu